2seventy bio, Inc. (NASDAQ:TSVT) COO Sells $11,375.10 in Stock

2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow sold 2,298 shares of 2seventy bio stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $11,375.10. Following the sale, the chief operating officer now owns 254,193 shares in the company, valued at $1,258,255.35. This represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

2seventy bio Price Performance

NASDAQ:TSVT opened at $4.95 on Friday. 2seventy bio, Inc. has a 12-month low of $2.29 and a 12-month high of $5.99. The firm has a market capitalization of $255.36 million, a P/E ratio of -2.66 and a beta of 1.73. The business has a 50 day simple moving average of $2.94 and a 200 day simple moving average of $3.71.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH acquired a new position in 2seventy bio during the 3rd quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. acquired a new position in 2seventy bio during the 4th quarter worth $32,000. BNP Paribas Financial Markets acquired a new position in 2seventy bio during the 4th quarter worth $35,000. ProShare Advisors LLC acquired a new position in 2seventy bio during the 4th quarter worth $48,000. Finally, Raymond James Financial Inc. acquired a new position in 2seventy bio during the 4th quarter worth $52,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TSVT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a report on Friday, March 7th. Leerink Partnrs downgraded 2seventy bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 11th. Morgan Stanley lowered their price target on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Friday, March 14th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $5.00 price target (down from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.67.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.